These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 19470043)

  • 1. Cutaneous adverse events related to glatiramer acetate injection (copolymer-1, Copaxone).
    Kluger N; Thouvenot E; Camu W; Guillot B
    J Eur Acad Dermatol Venereol; 2009 Nov; 23(11):1332-3. PubMed ID: 19470043
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone.
    Charach G; Grosskopf I; Weintraub M
    Digestion; 2008; 77(3-4):198-200. PubMed ID: 18607107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic reaction to glatiramer acetate.
    Bayerl C; Bohland P; Jung EG
    Contact Dermatitis; 2000 Jul; 43(1):62-3. PubMed ID: 10902605
    [No Abstract]   [Full Text] [Related]  

  • 4. Necrotizing skin lesions with involvement of muscle tissue after subcutaneous injection of glatiramer acetate.
    Feldmann R; Schierl M; Rauschka H; Sator PG; Breier F; Steiner A
    Eur J Dermatol; 2009; 19(4):385. PubMed ID: 19451051
    [No Abstract]   [Full Text] [Related]  

  • 5. Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma.
    Madray MM; Greene JF; Butler DF
    Arch Neurol; 2008 Oct; 65(10):1378-9. PubMed ID: 18852356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Livedo-like dermatitis (Nicolau's syndrome) after injection of Copolymer-1 (Glatiramer acetate)].
    Gaudez C; Regnier S; Aractingi S; Heinzlef O
    Rev Neurol (Paris); 2003 May; 159(5 Pt 1):571-3. PubMed ID: 12773903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow up of glatiramer acetate compassionate use in Belgium.
    Sindic CJ; Seeldrayers P; Vande Gaer L; De Smet E; Nagels G; De Deyn PP; Medaer R; Guillaume D; D'Hooghe MB; Deville MC; Decoo D; Sadzot B; Van Landegem W; Strauven T; Pepin J; Merckx H; Caekebeke J; van der Tool MA
    Acta Neurol Belg; 2005 Jun; 105(2):81-5. PubMed ID: 16076061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
    Ball NJ; Cowan BJ; Moore GR; Hashimoto SA
    J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rare and clinically relevant adverse reactions following subcutaneous administration of glatiramer acetate].
    Sevilla Ortiz M; Martínez Martínez L; Piñeiro Corrales G
    Farm Hosp; 2011; 35(3):160-1. PubMed ID: 21441052
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis.
    Thouvenot E; Hillaire-Buys D; Bos-Thompson MA; Rigau V; Durand L; Guillot B; Camu W
    Mult Scler; 2007 Aug; 13(7):941-4. PubMed ID: 17881403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe anaphylactic reaction to glatiramer acetate with specific IgE.
    Rauschka H; Farina C; Sator P; Gudek S; Breier F; Schmidbauer M
    Neurology; 2005 Apr; 64(8):1481-2. PubMed ID: 15851756
    [No Abstract]   [Full Text] [Related]  

  • 12. Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study.
    Soares Almeida LM; Requena L; Kutzner H; Angulo J; de Sa J; Pignatelli J
    J Am Acad Dermatol; 2006 Dec; 55(6):968-74. PubMed ID: 17097393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glatiramer in the treatment of multiple sclerosis.
    Rizvi SA; Kim E; Moodie J
    Int J Nanomedicine; 2006; 1(3):283-9. PubMed ID: 17717969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report.
    Hashimoto S; Ball Nj; Tremlett H
    Mult Scler; 2009 Apr; 15(4):521-2. PubMed ID: 19091880
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel.
    Korczyn AD; Nisipeanu P
    J Neurol; 1996 Apr; 243(4 Suppl 1):S23-6. PubMed ID: 8965117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glatiramer: new preparation. No place in multiple sclerosis.
    Prescrire Int; 2004 Feb; 13(69):10-2. PubMed ID: 15055208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis.
    Brod SA; Lindsey JW; Wolinsky JS
    Ann Neurol; 2000 Jan; 47(1):127-31. PubMed ID: 10632113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection.
    Aharoni R; Yussim A; Sela M; Arnon R
    Int Immunopharmacol; 2005 Jan; 5(1):23-32. PubMed ID: 15589456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.